These observations may be of clinical utility in patients undergoing Inotuzumab ozogamicin (InO) therapy and for the assessment of MRD in ALL patients who have been treated with anti-CD22 antibodies. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.